abstract |
plasmid sdf-1, injectable preparation and use of said preparation. a method of treating cardiomyopathy in an individual includes administering directly or expressing locally in a region of peri-infarction and / or weakened, ischemic, of the individual's myocardial tissue, an amount of sdf-1 effective to cause functional improvement in at least one of the following parameters: left ventricular volume, left ventricular area, left ventricular dimension, cardiac function, 6-minute walk test, or new york heart association (nyha) functional classification. |